Vasoinhibins and the pituitary gland

Frontiers of Hormone Research

Volumn 38, Issue , 2010, Pages 184-189

  Méndez, Isabel ^a,b   Vega, Claudia ^a   Zamorano, Miriam ^a   Moreno Carranza, Bibiana ^a   Martínez De La Escalera, Gonzalo ^a   Clapp, Carmen ^a  

^a CENTRO DE FÍSICA APLICADA Y TECNOLOGÍA AVANZADA   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; MATRIX METALLOPROTEINASE; PROCOLLAGEN C PROTEINASE; PROLACTIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; VASOINHIBIN;

HUMAN; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; NEUROHYPOPHYSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SUPRAOPTIC NUCLEUS;

EID: 84926102437     PISSN: 03013073     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000318509     Document Type: Review

References (31)

1. Mittra I: A novel 'cleaved prolactin' in the rat pituitary. I. Biosynthesis, characterization and regulatory control. Biochem Biophys Res Commun 1980; 95:1750.
2. Mittra I: A novel 'cleaved prolactin' in the rat pituitary. II. In vivo mammary mitogenic activity of its N-terminal 16K moiety. Biochem Biophys Res Commun 1980;95:1760.
3. Clapp C, Sears PS, Russell DH, Richards J, Levay-Young BK, Nicoll CS: Biological and immunological characterization of cleaved and 16K forms of rat prolactin. Endocrinology 1988;122:2892.
4. Clapp C, Aranda J, Gonzalez C, Jeziorski MC, Martinez de la Escalera G: Vasoinhibins: endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab 2006;17:301.
5. Clapp C, Torner L, Gutierrez-Ospina G, Alcantara E, Lopez-Gomez FJ, Nagano M, Kelly PA, Mejia S, Morales MA, Martinez de la Escalera G: The prolac-tin gene is expressed in the hypothalamic-neurohy-pophyseal system and the protein is processed into a 14-kDa fragment with activity like 16-kDa prolac-tin. Proc Natl Acad Sci USA 1994;91:10384.
6. Baldocchi RA, Tan L, King DS, Nicoll CS: Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. Endocrinology 1993;133:935.
7. Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA, Goffin V: Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 2004;18:2522.
8. Macotela Y, Aguilar MB, Guzman-Morales J, Rivera JC, Zermeno C, Lopez-Barrera F, Nava G, Lavalle C, Martinez de la Escalera G, Clapp C: Matrix metal-loproteases from chondrocytes generate an antian-giogenic 16 kDa prolactin. J Cell Sci 2006;119:1790.
9. Ge G, Fernandez CA, Moses MA, Greenspan DS: Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci USA 2007;104:10010.
10. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI: The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angio-genesis. Endocrinology 1993;133:1292.
11. Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA: Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 1999;96:1246.
12. Nguyen NQ, Tabruyn SP, Lins L, Lion M, Cornet AM, Lair F, Rentier-Delrue F, Brasseur R, Martial JA, Struman I: Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis. Proc Natl Acad Sci USA 2006;103:14319.
13. Clapp C, Thebault S, Martinez De La Escalera G: Roles of prolactin and vasoinhibins in the regulation of vascular function in mammary gland. J Mammary Gland Biol Neoplasia 2008;13:55.
14. Garcia C, Aranda J, Arnold E, Thebault S, Macotela Y, Lopez-Casillas F, Mendoza V, Quiroz-Mercado H, Hernandez-Montiel HL, Lin SH, De La Escalera GM, Clapp C: Vasoinhibins prevent retinal vasoper-meability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest 2008;118:2291.
15. Gonzalez C, Corbacho AM, Eiserich J P, Garcia C, Lopez-Barrera F, Morales-Tlalpan V, Barajas-Espinosa A, Diaz-Munoz M, Rubio R, Lin SH, Martinez De La Escalera G, Clapp C: 16K-prolactin inhibits activation of endothelial nitric oxide syn-thase, intracellular calcium mobilization, and endo-thelium-dependent vasorelaxation. Endocrinology 2004;145:5714.
16. Aranda J, Rivera JC, Jeziorski MC, Riesgo-Escovar J, Nava G, Lopez-Barrera F, Quiroz-Mercado H, Berger P, Martinez De La Escalera G, Clapp C: Pro-lactins are natural inhibitors of angiogenesis in the retina. Invest Ophthalmol Vis Sci 2005;46:2947.
17. Clapp C, Thebault S, Arnold E, Garcia C, Rivera JC, De La Escalera GM: Vasoinhibins: novel inhibitors of ocular angiogenesis. Am J Physiol Endocrinol Metab 2008;295:E772.
18. Shah GN, Hymer WC: Prolactin variants in the rat adenohypophysis. Mol Cell Endocrinol 1989;61:97.
19. Sinha YN, Gilligan TA, Lee DW, Hollingsworth D, Markoff E: Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. J Clin Endocrinol Metab 1985;60:239.
20. Sinha YN, Gilligan TA: A cleaved form of prolactin in the mouse pituitary gland: identification and comparison of in vitro synthesis and release in strains with high and low incidences of mammary tumors. Endocrinology 1984;114:2046.
21. Cruz-Soto M, Cosío G, Jeziorski MC, Vargas-Barraso V, Aguilar MB, Carabez A, Berger P, Satfig P, Thebault S, Martínez De La Escalera G, Clapp C: Cathepsin D is a primary protease for the generation of adenohypo-physeal vasoinhibins: cleavage occurs within the pro-lactin secretory granules. Endocrinology 2009;150: 5446.
22. Khurana S, Liby K, Buckley AR, Ben-Jonathan N: Proteolysis of human prolactin: resistance to cathe-psin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology 1999;140:4127.
23. Andries M, Tilemans D, Denef C: Isolation of cleaved prolactin variants that stimulate DNA synthesis in specific cell types in rat pituitary cell aggregates in culture. Biochem J 1992;281:393.
24. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL: Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000;6:15.
25. Cosio G, Jeziorski MC, Lopez-Barrera F, De La Escalera GM, Clapp C: Hypoxia inhibits expression of prolactin and secretion of cathepsin-D by the GH4C1 pituitary adenoma cell line. Lab Invest 2003;83:1627.
26. Turner HE, Harris AL, Melmed S, Wass JA: Angio-genesis in endocrine tumors. Endocr Rev 2003;24: 600.
27. Torner L, Mejia S, Lopez-Gomez FJ, Quintanar A, Martinez De La Escalera G, Clapp C: A 14-kilodalton prolactin-like fragment is secreted by the hypo-thalamo-neurohypophyseal system of the rat. Endocrinology 1995;136:5454.
28. Mejia S, Morales MA, Zetina ME, Martinez De La Escalera G, Clapp C: Immunoreactive prolactin forms colocalize with vasopressin in neurons of the hypothalamic paraventricular and supraoptic nuclei. Neuroendocrinology 1997;66:151.
29. Torner L, Nava G, Duenas Z, Corbacho A, Mejia S, Lopez F, Cajero M, Martinez De La Escalera G, Clapp C: Changes in the expression of neurohypophyseal prolactins during the estrous cycle and after estrogen treatment. J Endocrinol 1999;161:423.
30. Alonso G, Gallibert E, Lafont C, Guillon G: Intrahypothalamic angiogenesis induced by osmotic stimuli correlates with local hypoxia: a potential role of confined vasoconstriction induced by dendritic secretion of vasopressin. Endocrinology 2008; 149:4279.
31. Mejia S, Torner LM, Jeziorski MC, Gonzalez C, Morales MA, De La Escalera GM, Clapp C: Prolactin and 16K prolactin stimulate release of vasopressin by a direct effect on hypothalamo-neurohypophy-seal system. Endocrine 2003;20:155.